Gilead Sciences, Inc. Sorry, your browser does not support JavaScript! Medicine Questions Report an Adverse Event Investors Contact Global Operations North America Canada Mexico USA South America Argentina Brazil Colombia Asia China Mainland Hong Kong India Japan Korea Singapore Taiwan Middle East Israel Saudi Arabia Türkiye United Arab Emirates Africa South Africa Australia Australia and New Zealand Europe Austria Belgium and Luxembourg Czech Republic & Slovakia Denmark Finland France Germany Greece Iceland Ireland Italy Netherlands Norway Poland & The Baltics Portugal Romania Russia Spain Sweden Switzerland United Kingdom Our Company About Us Leadership U.S. Public Policy Engagement Policies and Disclosures Supplier Information U.S. Locations Our Purpose Partnerships and Community Corporate Giving Gilead Foundation Inclusion and Diversity Environmental, Social, Governance (ESG) Sustainability Advancing Global Health Health Equity Medication Access Science & Medicine Our Therapeutic Areas Medicines Pipeline Research Clinical Trials Diversity in Clinical Trials News and Press Events Stories Newsroom Company Statements Annual Reports Careers Careers at Gilead Our Culture Meet Our Employees Inclusion and Diversity in Hiring Compensation, Benefits and Wellbeing Our Global Footprint Early Career Opportunities Postdoctoral Fellowships Hiring Events Talent Community Sign-up Utility Privacy Statements Terms Of Use Social Media Guidelines Sitemap BACK TO MAIN MENU Leadership Governance and Committees BACK TO MAIN MENU U.S. Public Policy Engagement Political Contributions Archives BACK TO MAIN MENU Policies and Disclosures Policies Disclosures BACK TO MAIN MENU Supplier Information Supplier Enablement Resources Supplier Inclusion BACK TO MAIN MENU Partnerships and Community COMPASS Initiative HepConnect HIV Age Positively Setting the P.A.C.E. Toward Health Equity for Black People Impacted by TNBC Toward Health Equity Oncology Grant RADIAN TRANScend Zeroing In: Ending the HIV Epidemic Zeroing In: Latin America & The Caribbean (LAC) Region BACK TO MAIN MENU Corporate Giving What We Fund Funding Requests BACK TO MAIN MENU Gilead Foundation Creating Possible Fund BACK TO MAIN MENU Environmental, Social, Governance (ESG) Reporting U.N. Global Compact BACK TO MAIN MENU Sustainability Our Business Is Sustainable Performance BACK TO MAIN MENU Advancing Global Health COVID-19 HCV Elimination BACK TO MAIN MENU Medication Access U.S. Patient Access Global Access Authorized Distributors BACK TO MAIN MENU Our Therapeutic Areas Virology Oncology Inflammation BACK TO MAIN MENU Research Research Scholars Program Compassionate Use Community Based Participatory Research (CBPR) Investigator-Sponsored Research BACK TO MAIN MENU Newsroom Press Releases Media Inquiries BACK TO MAIN MENU Early Career Opportunities Internship Program BACK TO MAIN MENU Privacy Statements Cookie Statement Global Applicant Privacy Statement Healthcare Professional Privacy Notice - U.S. only Healthcare Professional Privacy Notice BACK TO MAIN MENU North America Canada Mexico USA South America Argentina Brazil Colombia Asia China Mainland Hong Kong India Japan Korea Singapore Taiwan Middle East Israel Saudi Arabia Türkiye United Arab Emirates Africa South Africa Australia Australia and New Zealand Europe Austria Belgium and Luxembourg Czech Republic & Slovakia Denmark Finland France Germany Greece Iceland Ireland Italy Netherlands Norway Poland & The Baltics Portugal Romania Russia Spain Sweden Switzerland United Kingdom BACK TO MAIN MENU Contact Request Medicines Information Report an Adverse Event Partnership Request Search Term Medicine Questions Report an Adverse Event Investors Contact Global Operations Toggle Inner Dropdown BACK TO MAIN MENU Google.com New Era Marked by Innovation, Growth and Impact 2024 marks a new era for Gilead. We’re looking forward to innovation, continued growth and making an even greater impact as we advance our leading HIV prevention and treatment portfolio and accelerate cutting-edge treatments for cancer. Our Purpose Scientific Innovation We discover, develop and deliver medicines for the world’s most devastating diseases, from viruses to cancer to inflammatory conditions. Access & Health Equity We’re partnering with communities around the world to remove societal barriers to care, improve health equity and make our medicines available to those who need them most. Our People & Culture We foster an environment of inclusion and growth where our 17,000+ employees around the world are empowered to make a real impact. We’ve been taking on the world’s biggest health challenges for more than 35 years. We continue to set and achieve ambitious goals to create a healthier world for all people. Our Mission Recent Stories Access and Health Equity Winn Awards Help Physicians Solve Healthcare Disparities Stories@Gilead - February 28, 2024 - 5 min read Scientific Innovation Gilead Sets Sights on Hepatitis C Elimination as it Marks 10 years of Curative Therapies Stories@Gilead - January 29, 2024 - 4 min read Access and Health Equity From the Margins: Gilead's Book Uniquely Captures What it's Like to be Marginalized by Disease Stories@Gilead - January 23, 2024 - 1 min read Recent News February 27, 2024 Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. February 26, 2024 U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance Join Our Team We're Hiring © 1996-2023 Gilead Sciences, Inc. All rights reserved. AREAS OF INTEREST Careers Environmental, Social, Governance (ESG) Medicines Partnerships and Community Pipeline Stories@Gilead INFORMATION Contact Us Investor Calls Press Room Report an Adverse Event Sitemap LEGAL Cookie Statement Modern Slavery Act Statement Privacy Statement Public Policy Engagement Social Media Guidelines Terms of Use FOLLOW US Headline Close × Intersititial body copy Ok Cancel Close × Welcome Some content on this site is not intended for people outside the United States. Accept